Monitoring PML-RARα in acute promyelocytic leukemia

Current Oncology Reports

Volumn 5, Issue 5, 2003, Pages 391-398

  Jurcic, Joseph G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHENYLBUTYRIC ACID; ABELSON KINASE; ARSENIC TRIOXIDE; CD33 ANTIGEN; CYTARABINE; GEMTUZUMAB OZOGAMICIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IDARUBICIN; MESSENGER RNA; MITOXANTRONE; MONOCLONAL ANTIBODY; PORPHOBILINOGEN DEAMINASE; PROMYELOCYTIC LEUKEMIA PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR ALPHA; ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; PROMYELOCYTIC LEUKEMIA-RETINOIC ACID RECEPTOR ALPHA FUSION ONCOPROTEIN; TUMOR PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS BONE MARROW TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER MODEL; CANCER RECURRENCE; CHROMOSOME TRANSLOCATION 15; CHROMOSOME TRANSLOCATION 17; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; DRUG RESPONSE; DRUG TARGETING; GENE AMPLIFICATION; GENETIC DISORDER; GENETIC SCREENING; HUMAN; MEDICAL DECISION MAKING; MINIMAL RESIDUAL DISEASE; MOLECULAR GENETICS; PATIENT MONITORING; PREDICTION; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SALVAGE THERAPY; STANDARDIZATION; TREATMENT PLANNING; ACUTE DISEASE; GENETICS; METABOLISM; MONITORING; RECURRENT DISEASE; REMISSION;

ACUTE DISEASE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MONITORING, PHYSIOLOGIC; NEOPLASM PROTEINS; ONCOGENE PROTEINS, FUSION; PROGNOSIS; RECURRENCE; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SALVAGE THERAPY;

EID: 2142805764     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-003-0025-7     Document Type: Review

References (67)

1. Huang ME, Ye YC, Chen SR, et al.: Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988, 72:567-572.
2. Castaigne S, Chomienne C, Daniel MT, et al.: All-trans retinoic acid as a differentiation therapy for acute promyelocytic leukemia. I. Clinical results. Blood 1990, 76:1704-1709.
3. Warrell RP Jr, Frankel SR, Miller WH Jr, et al.: Differentiation therapy of acute promyelocytic leukemia with tretinoin (all-trans-retinoic acid). N Engl J Med 1991, 324:1385-1393.
4. Warrell RP Jr, Maslak PG, Eardley A, et al.: Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia 1994, 8:929-933.
5. Tallman MS, Anderson JW, Schiffer CA, et al.: All-trans retinoic acid in acute promyelocytic leukemia. N Engl J Med 1997, 337:1021-1028.
6. Mandelli F, Diverio D, Avvisati G, et al.: Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997, 90:1014-1021.
7. Fenaux P, Chastang C, Chevret S, et al.: A randomized comparison of all-trans retinoic acid (ATRA) following chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:1192-1200.
8. Shen Z-X, Chen G-Q, Ni J-H, et al.: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapse patients. Blood 1997, 89:3345-3360.
9. Soignet SL, Maslak P, Wang Z-G, et al.: Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998, 339:1341-1348.
10. Soignet SL, Frankel SR, Douer D, et al.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol 2001, 19:3852-3860.
11. Estey E, Thall PF, Pierce S, et al.: Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 1997, 15:483-490.
12. Sanz MA, LoCoco F, Martín G, et al.: Definition of relapse risk and role of nonanthracycline drugs for consolidation in patients with acute promyelocytic leukemia: a joint study of the PETHEMA and GIMEMA cooperative groups. Blood 2000, 96:1247-1253.
13. de Thé H, Chomienne C, Lanotte M, et al.: The t(15;17) translocation of acute promyelocytic leukaemia fuses the retinoic acid receptor α gene to a novel transcribed locus. Nature 1990, 347:558-561.
14. Miller WH Jr, Warrell RP Jr, Frankel SR, et al.: Novel retinoic acid receptor-α transcripts in acute promyelocytic leukemia responsive to all-trans retinoic acid. J Natl Cancer Inst 1990, 32:1932-1933.
15. Kakizuka A, Miller WH Jr, Umesono K, et al.: Chromosomal translocation t(15;17) in human acute promyelocytic leukemia fuses RAR-alpha with a novel putative transcription factor, PML. Cell 1991, 66:663-674.
16. de Thé H, Lavau C, Marcio A, et al.: The PML-RAR-α fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR. Cell 1991, 66:675-684.
17. Salomoni P, Pandolfi PP: The role of PML in tumor suppression. Cell 2002, 108:165-70.
18. Kastner P, Chan S: Function of RARα during the maturation of neutrophils. Oncogene 2001, 20:7216-7222.
19. Miller WH Jr, Kakizuka A, Frankel SR, et al.: Reverse transcription polymerase chain reaction for the rearranged retinoic acid receptor-α clarifies diagnosis and detects minimal residual disease in acute promyelocytic leukemia. Proc Natl Acad Sci U S A 1992, 89:2694-2698.
20. Borrow J, Goddard AD, Gibbons B, et al.: Diagnosis of acute promyelocytic leukaemia by RT-PCR: detection of PML-RARalpha and RAR-PML fusion transcripts. Br J Haematol 1992, 82:529-540.
21. Pandolfi PP, Alcalay M, Fagioli M, et al.: Genomic variability and alternative splicing generate multiple PML/RARα transcripts that encode aberrant PML proteins and PML/RARalpha isoforms in acute promyelocytic leukemia. EMBO J 1992, 11:1397-1407.
22. Biondi A, Rambaldi A, Pandofi PP, et al.: Molecular monitoring of my1/RAR-alpha fusion gene in acute promyelocytic leukemia by polymerase chain reaction. Blood 1992, 80:492-97.
23. Chen S-J, Zelent A, Tong J-H, et al.: Rearrangements of the retinoic acid receptor a and promyelocytic zinc finger genes resulting from t(11;17)(q23;q21) in a patients with acute promyelocytic leukemia. J Clin Invest 1993, 91:2260-2267.
24. Redner RL, Rush EA, Faas S, et al.: The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood 1996, 87:882-886.
25. Wells RA, Catzavelos C, Kamel-Reid S. Fusion of retinoic acid receptor α to NUMA, the nuclear mitotic apparatus protein, by a variant translocation in acute promyelocytic leukemia. Nat Genet 1997, 17:109-113.
26. Arnould C, Philippe C, Bourdon V, et al.: The signal transducer and activator of transcription STAT5b gene is a new partner of retinoic acid receptor α in acute promyelocytic-like leukemia. Human Mol Genet 1999, 8:1741-1749.
27. Grimwade D, Biondi A, Mozziconacci M-J, et al.: Characterization of acute promyelocytic leukemia cases lacking the classic t(15;17): results of the European Working Party. Blood 2000, 96:1297-1308.
28. Biondi A, Rambaldi A, Alcalay M, et al.: RAR-alpha rearrangements as a genetic marker for diagnosis and monitoring in acute promyelocytic leukemia. Blood 1991, 77:1418-1422.
29. Castaigne S, Balitrand N, de Thé H, et al.: A PML/retinoic acid receptor-α fusion transcript is constantly detected by RNA-based polymerase chain reaction in acute promyelocytic leukemia. Blood 1992, 79:3110-3115.
30. Burnett AK, Grimwade D, Solomon E, et al.: Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the randomized MRC trial. Blood 1999, 93:4131-4143.
31. Zhang P, Wang S, Hu X, et al.: Arsenic trioxide treated 72 cases of acute promyelocytic leukemia. Chin J Hematol 1996, 17:58-62.
32. Gallagher R, Willman CL, Slack JL, et al.: Association of PML/RARalpha fusion mRNA type with pre-treatment hematologic characteristics but not treatment outcome in acute promyelocytic leukemia: an intergroup molecular study. Blood 1997, 90:1656-1663.
33. Huang W, Sun G-L, Li Z-S, et al.: Acute promyelocytic leukemia: clinical relevance of two major PML-RARalpha isoforms and detection of minimal residual disease by retrotranscriptase/polymerase chain reaction to predict relapse. Blood 1993, 82:1264-1269.
34. Jurcic JG, Nimer SD, Scheinberg DA, et al.: Prognostic significance of minimal residual disease detection and PML/RARalpha isoform type: long-term follow-up in acute promyelocytic leukemia. Blood 2001, 98:2651-2656.
35. Slack JL, Willman CL, Andersen JW, et al.: Molelcular analysis and clinical outcome of adult APL patients with the type V PML-RARalpha isoform: results from Intergroup protocol 0129. Blood 2000, 95:398-403.
36. Allford S, Grimwade D, Langabeer S, et al.: Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML-RARalpha rearrangement in newly diagnosed AML. Br J Haematol 1999, 114:551-556.
37. Mandelli F, Diverio D, Avvisati G, et al.: Molecular remission in PML/RARalpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 1997, 90:1014-1021.
38. Niu C, Yan H, Yu T, et al.: Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood 1999, 94:3315-3324.
39. Bonnet D, Dick JE: Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
40. Jurcic JG, DeBlasio T, Dumont L, et al.: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM95 in acute promyelocytic leukemia. Clin Cancer Res 2000, 6:372-380.
41. Estey EH, Giles FJ, Beran M, et al.: Experience with gemtuzumab ozogamicin ('Mylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood 2002, 99:4222-4224.
42. Estey EH, Giles FJ, Kantarjian H, et al.: Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 1999, 94:2230-2235.
43. Lin R, Nagy L, Inoue S, et al.: Role of the histone deacetylase complex in acute promyelocytic leukemia. Nature 1998, 391:811-814.
44. Warrell RP, He L-Z, Ricon V, et al.: Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 1998, 90:1621-1625.
45. Zhou DC, Kim SH, Ding W, et al.: Frequent mutations in the ligand-binding domain of PML-RARalpha after multiple relapses of acute promyelocytic leukemia: analysis for functional relationship to responses to all-trans retinoic acid and histone deacetylase inhibitors in vitro and in vivo. Blood 2002, 99:1356-1363.
46. Seale JRC, Varma S, Swirsky DM, et al.: Quantification of PML/RARα transcripts in acute promyelocytic leukaemia: explanation for lack of sensitivity of RT-PCR for the detection of minimal residual disease and induction of leukaemia-specific mRNA by alpha interferon. Br J Haematol 1996, 95:95-101.
47. Tobak K, Moore H, Macheta Liu Yin HA: Monitoring minimal residual disease and predicting relapse in APL by quantitating PML-RARalpha transcripts with a sensitive competitive RT-PCR method. Leukemia 2001, 15:1060-1065.
48. Diverio D, Rossi V, Avvisati G, et al.: Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter 'AIDA' trial. Blood 1998, 92:784-789.
49. LoCoco F, Diverio D, Pandolfi PP, et al.: Molecular evaluation of residual disease as a predictor of relapse in acute promyelocytic leukemia. Lancet 1992, 340:1437-1438.
50. Miller WH Jr, Levine K, DeBlasio A, et al.: Detection of minimal residual disease in acute promyelocytic leukemia by a reverse transcription polymerase chain reaction. Blood 1993, 82:1689-1694.
51. Diverio D, Pandolfi PP, Biondi A, et al.: Absence of RT-PCR detectable residual disease in acute promyelocytic leukemia in long-term remission. Blood 1993, 82:3556-3559.
52. Ikeda K, Sasaki K, Tasaka T, et al.: Reverse transcription-polymerase chain reaction for PML-RARalpha fusion transcripts in acute promyelocytic leukemia and its application to minimal residual disease detection. Leukemia 1993, 7:544-548.
53. Fukutani H, Naoe T, Ohno R, et al.: Prognostic significance of the RT-PCR assay of PML-RARalpha transcripts in acute promyelocytic leukemia. Leukemia 1995, 9:588-593.
54. LoCoco F, Diverio D, Avvisati G, et al.: Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999, 94:2225-2229.
55. Meloni G, Diverio D, Vignetti M, et al.: Autologous bone marrow transplantation for acute promyelocytic leukemia in second remission: prognostic relevance of pretransplant minimal residual disease assessment by reverse-transcription polymerase chain reaction of the PML/RARalpha fusion gene. Blood 1997, 90:1321-1325.
56. Sanz MA, de la Rubia J, Bonanad S, et al.: Prolonged molecular remission after PML/RARalpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: Is relevant pretransplant minimal residual disease in the graft? Leukemia 1998, 12:992-995.
57. Thomas X, Dombret H, Cordonnier C, et al.: Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid followed by timed sequential chemotherapy and stem cell transplantation. Leukemia 2000, 14:1006-1013.
58. Grimwade D: The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring the management of the disease. Br J Haematol 1999, 106:591-613.
59. Román J, Martín C, Torres A, et al.: Absence of detectable PML-RARalpha fusion transcripts in long-term remission patients after BMT for acute promyelocytic leukemia. Bone Marrow Transplant 1997, 19:679-983.
60. Grimwade D, Jamal R, Goulden N, et al.: Salvage of patients with acute promyelocytic leukaemia with residual disease following ABMT performed in second complete remission using all-trans retinoic acid. Br J Haematol 1998, 103:559-562.
61. Fukutani H, Naoe T, Ohno R, et al.: Isoforms of PML-retinoic acid receptor alpha fused transcripts affect neither clinical features of acute promyelocytic leukemia nor prognosis after treatment with all-trans retinoic acid. Leukemia 1995, 9:1478-1482.
62. Diverio D, Riccioni R, Pistilli A, et al.: Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia. Leukemia 1996, 10:1214-1216.
63. Tobal K, Liu Yin JA. RT-PCR method with increased sensitivity shows persistence of PML-RARalpha fusion transcripts in patients in long-term remission of APL. Leukemia 1998, 12:1349-1354.
64. Slack JL, Bi W, Livak KJ, et al.: Pre-clinical validation of a novel, highly sensitive assay to detect PML-RARalpha mRNA using real-time reverse-transcription polymerase chain reaction. J Mol Diagn 2001, 3:141-149.
65. Cassinat B, Zassadowski F, Balitrand N, et al.: Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR. Leukemia 2000, 14:324-328.
66. Visani G, Buonamici S, Malagola M, et al.: Pulsed ATRA as single therapy restores long-term remission in PML-RARalpha-positive acute promyelocytic leukemia patients: real time quantification of minimal disease. A pilot study. Leukemia 2001, 15:1696-1700.
67. Gallagher RE, Yeap BY, Bi W, et al.: Quantitative real-time RT-PCR analysis of PML-RARalpha mRNA in acute promyelocytic leukemia: assessment of prognostic significance in adult patients from intergroup protocol 0129. Blood 2003, 101:2521-2528.